Strata Critical Medical (SRTA) Common Equity (2019 - 2026)

Strata Critical Medical has disclosed Common Equity across 8 years of filings, most recently posting $285.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 30.04% year-over-year to $285.7 million; the TTM figure through Mar 2026 stood at $285.7 million (up 30.04% YoY), while the FY2025 annual figure was $279.1 million, up 25.74% from the prior year.
• Common Equity advanced to $285.7 million in Q1 2026, from $279.1 million in the prior quarter.
• Over the last five years, Common Equity for SRTA reached as high as $292.3 million in Q2 2022 and fell as low as $219.7 million in Q1 2025.
• The 5-year median for Common Equity is $262.9 million (2023), against an average of $257.1 million.
• Annual changes were most pronounced in 2022 — Common Equity surged 3557.35% — and 2023, when it decreased 14.64%.
• A 5-year view of Common Equity shows it stood at $274.5 million in 2022, then declined by 14.64% to $234.3 million in 2023, then declined by 5.28% to $221.9 million in 2024, then gained by 25.74% to $279.1 million in 2025, then advanced by 2.39% to $285.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $285.7 million, $279.1 million, and $283.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.